leisure time -WSS

leisure time

author：explore 2025-09-29 21:23:05 - browse：77

Amid the stunning rebuke Amgen suffered at the hands of the U.S. Food and Drug Administration this week lurk numerous questions. And one of them may be whether the company was fully forthcoming about a pricey lung cancer drug that is supposed to generate key revenue growth.

At issue is a trial that Amgen is relying upon to win final approval for Lumakras, which the FDA approved on a conditional basis in 2021. This process, known as accelerated approval, required the company to run a confirmatory study. But ahead of an advisory panel meeting on Thursday, the agency released documents showing its staff found “potential systemic bias” in the trial.

The disclosure throws into question the future of this drug, which has offered hope to patients for whom an effective treatment previously seemed out of reach. Some Wall Street analysts are now betting the FDA will ask Amgen to run yet another trial or maybe withdraw the drug altogether. Either way, the prognosticators are reworking their calculus for Amgen stock.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： BioMarin wins approval for gene therapy to treat hemophilia A
Next article： The haunting brain science of long Covid

Wikipedia

explore

hotspot

WSS

Biden warns of ‘dark winter’ during final presidental debate

STAT Virtual Event: Putting AI to the Test

What Congress can do to address the rural doctor shortage

Ukraine and a new approach to mental health in war

STAT Report: Patient voices and perspectives

What it's like to live with paralysis for one psychologist

knowledge

leisure time

focus

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Senators: Long

Wildfire smoke exposes gaps in outdoor worker protections

Search called off for baby washed away in Pennsylvania flash flood

Apple is now the first public company to be valued at $3 trillion

CDC advisers recommend seasonal use of Pfizer RSV shot

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Why patients can’t get everything they want on drug pricing

Wildfire smoke exposes gaps in outdoor worker protections

CommonSpirit Health keeps growing, even as it loses money

knowledge

'Investigate these claims': UFO transparency at center of House hearing

FDA panel to weigh approval of NurOwn, controversial ALS drug

Medical student insurance fails on mental health care coverage

Hearing on Medicare drug price negotiation gets unusually heated

Readout LOUD podcast: possible new ALS drug, artificial wombs

How AI helped researchers track recovery from depression

Wikipedia

explore

hotspot

focus